Medibio (ASX: MEB) (OTC: MDBIF) CEO Interview with David Kaysen. Mr. Kaysen recently came on board as the new CEO, in this interview he discusses Medibio’s mental health monitoring technologies, ongoing progress towards full-scale commercializing, and his background in running small-cap med-tech companies. Kaysen sees 2019 as a “very important year for Medibio” with commercialization rollout, capital raising and FDA regulatory approvals.